Pharma Mar, S.A. (PHMMF)

Market Cap	1.59B
Revenue (ttm)	189.96M
Net Income (ttm)	21.48M
Shares Out	n/a
EPS (ttm)	n/a
PE Ratio	74.19
Forward PE	20.20
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Average Volume	2,806
Open	96.20
Previous Close	92.57
Day's Range	92.57 - 96.20
52-Week Range	34.26 - 105.60
Beta	-0.11
RSI	38.25
Earnings Date	Jul 25, 2025

About Pharma Mar

Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata for the treatment of soft tissue sarcoma and recurrent ovarian cancer; Aplidin i...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1986
• Employees: 500
• Stock Exchange: OTCMKTS
• Ticker Symbol: PHMMF

Financial Performance

In 2024, Pharma Mar's revenue was 174.86 million, an increase of 10.56% compared to the previous year's 158.15 million. Earnings were 26.13 million, an increase of 2197.71%.

Financial numbers in EUR